Share

Running Team to raise support for EORTC cancer research at Belfius Brussels Marathon

The EORTC Running Team plans to participate in the Belfius Brussels Marathon and Half Marathon on Sunday, 4 October 2015. This is an event that gladly supports organizations such as the EORTC who participate in order to benefit a good cause (FR, NL, EN).

The proceeds raised by Team EORTC will go towards supporting EORTC projects that improve treatments for patients with cancer. Please feel free to join the team, and you can support them and the EORTC with your donation.

The races at Belfius Brussels Mathon and Half Marathon include not only the marathon and half marathon, but also a 5km run and a one kilometer chiquita kids run. The EORTC Running Team anticipates that 10 -15 members of the EORTC Headquarters staff will take part in this event.

The EORTC Running Team has already participated in several other events in the past, e.g. the Brussels Marathon 2014, La Bruxelloise – Urban Woman Jogging, the Antwerp 10 miles & Marathon, the 20 km Brussels, the Brussels urban trail, etc., and is eager to welcome new members to join the fun.

Whether you are a child or a senior, a walker or a marathoner, you can take part in their program, and you can also count on seeing Team EORTC continue their efforts by participating in future events. As an added bonus, team members are provided dry-fit EORTC t-shirts.

Team EORTC points out that exercise is one of twelve ways to reduce your cancer risk as listed in the European Code Against Cancer.

John Bean, PhD
EORTC, Medical Science Writer

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023